These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37199884)

  • 21. Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
    Hayashi S; Tachibana S; Maeda T; Yamashita M; Shirasugi I; Yamamoto Y; Yamada H; Okano T; Nishimura K; Ueda Y; Jinnno S; Saegusa J; Yamamoto W; Murata K; Fujii T; Hata K; Yoshikawa A; Ebina K; Etani Y; Yoshida N; Amuro H; Hashimoto M; Hara R; Katayama M; Okano T; Kuroda R
    Rheumatology (Oxford); 2023 Nov; ():. PubMed ID: 37924201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis.
    Combe B; Besuyen R; Gómez-Centeno A; Matsubara T; Sancho Jimenez JJ; Yin Z; Buch MH
    Rheumatol Ther; 2023 Feb; 10(1):35-51. PubMed ID: 36205910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
    Burmester GR; Kremer JM; Van den Bosch F; Kivitz A; Bessette L; Li Y; Zhou Y; Othman AA; Pangan AL; Camp HS
    Lancet; 2018 Jun; 391(10139):2503-2512. PubMed ID: 29908669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE.
    Mysler E; Tanaka Y; Kavanaugh A; Aletaha D; Taylor PC; Song IH; Shaw T; Song Y; DeMasi R; Ali M; Fleischmann R
    Rheumatology (Oxford); 2023 May; 62(5):1804-1813. PubMed ID: 36018230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
    Smolen JS; Pangan AL; Emery P; Rigby W; Tanaka Y; Vargas JI; Zhang Y; Damjanov N; Friedman A; Othman AA; Camp HS; Cohen S
    Lancet; 2019 Jun; 393(10188):2303-2311. PubMed ID: 31130260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials.
    Bergman M; Buch MH; Tanaka Y; Citera G; Bahlas S; Wong E; Song Y; Zueger P; Ali M; Strand V
    Rheumatol Ther; 2022 Dec; 9(6):1517-1529. PubMed ID: 36125701
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
    Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
    Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
    Burmester GR; Strand V; Rubbert-Roth A; Amital H; Raskina T; Gómez-Centeno A; Pena-Rossi C; Gervitz L; Thangavelu K; St John G; Boklage S; Genovese MC
    RMD Open; 2019; 5(2):e001017. PubMed ID: 31673415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
    Kaine J; Tesser J; Takiya L; DeMasi R; Wang L; Snyder M; Soma K; Fan H; Bandi V; Wollenhaupt J
    Clin Rheumatol; 2020 Jul; 39(7):2127-2137. PubMed ID: 32048083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.
    Vermeire S; Danese S; Zhou W; Ilo D; Klaff J; Levy G; Yao X; Chen S; Sanchez Gonzalez Y; Hébuterne X; Lindsay JO; Higgins PDR; Cao Q; Nakase H; Colombel JF; Loftus EV; Panaccione R
    Lancet Gastroenterol Hepatol; 2023 Nov; 8(11):976-989. PubMed ID: 37683686
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
    Papp KA; Krueger JG; Feldman SR; Langley RG; Thaci D; Torii H; Tyring S; Wolk R; Gardner A; Mebus C; Tan H; Luo Y; Gupta P; Mallbris L; Tatulych S
    J Am Acad Dermatol; 2016 May; 74(5):841-50. PubMed ID: 26899199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.
    Fleischmann R; Mysler E; Bessette L; Peterfy CG; Durez P; Tanaka Y; Swierkot J; Khan N; Bu X; Li Y; Song IH
    RMD Open; 2022 Feb; 8(1):. PubMed ID: 35121639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
    Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
    Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
    Feagan BG; Panés J; Ferrante M; Kaser A; D'Haens GR; Sandborn WJ; Louis E; Neurath MF; Franchimont D; Dewit O; Seidler U; Kim KJ; Selinger C; Padula SJ; Herichova I; Robinson AM; Wallace K; Zhao J; Minocha M; Othman AA; Soaita A; Visvanathan S; Hall DB; Böcher WO
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):671-680. PubMed ID: 30056030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
    Burmester GR; Winthrop K; Blanco R; Nash P; Goupille P; Azevedo VF; Salvarani C; Rubbert-Roth A; Lesser E; Lippe R; Lertratanakul A; Mccaskill RM; Liu J; Ruderman EM
    Rheumatol Ther; 2022 Apr; 9(2):521-539. PubMed ID: 34970731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn's Disease in the CELEST Extension Study.
    D'Haens G; Panés J; Louis E; Lacerda A; Zhou Q; Liu J; Loftus EV
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2337-2346.e3. PubMed ID: 34968730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials.
    Mease P; Kavanaugh A; Gladman D; FitzGerald O; Soriano ER; Nash P; Feng D; Lertratanakul A; Douglas K; Lippe R; Gossec L
    Rheumatol Ther; 2022 Aug; 9(4):1181-1191. PubMed ID: 35606663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan.
    Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Song YW; Chen YH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y
    Rheumatol Ther; 2021 Mar; 8(1):425-442. PubMed ID: 33656739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis.
    Fleischmann R; Strand V; Wilkinson B; Kwok K; Bananis E
    RMD Open; 2016; 2(1):e000232. PubMed ID: 27175296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis.
    Li ZG; Liu Y; Xu HJ; Chen ZW; Bao CD; Gu JR; Zhao DB; An Y; Hwang LJ; Wang L; Kremer J; Wu QZ
    Chin Med J (Engl); 2018 Nov; 131(22):2683-2692. PubMed ID: 30425195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.